108 related articles for article (PubMed ID: 32515069)
21. Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.
Voso MT; Niscola P; Piciocchi A; Fianchi L; Maurillo L; Musto P; Pagano L; Mansueto G; Criscuolo M; Aloe-Spiriti MA; Buccisano F; Venditti A; Tendas A; Piccioni AL; Zini G; Latagliata R; Filardi N; Fragasso A; Fenu S; Breccia M;
Eur J Haematol; 2016 Apr; 96(4):344-51. PubMed ID: 26018238
[TBL] [Abstract][Full Text] [Related]
22. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Strati P; Kantarjian H; Ravandi F; Nazha A; Borthakur G; Daver N; Kadia T; Estrov Z; Garcia-Manero G; Konopleva M; Rajkhowa T; Durand M; Andreeff M; Levis M; Cortes J
Am J Hematol; 2015 Apr; 90(4):276-81. PubMed ID: 25530214
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Falantes JF; Trujillo P; Piruat JI; Calderón C; Márquez-Malaver FJ; Martín-Antonio B; Millán A; Gómez M; González J; Martino ML; Montero I; Parody R; Espigado I; Urbano-Ispizua A; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):236-44. PubMed ID: 25487600
[TBL] [Abstract][Full Text] [Related]
25. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.
Craddock C; Labopin M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis JH; Sengelov H; Blaise D; Luft T; Hallek M; Kröger N; Nagler A; Mohty M
Haematologica; 2016 Jul; 101(7):879-83. PubMed ID: 27081178
[TBL] [Abstract][Full Text] [Related]
26. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
Tsirogianni M; Grigoriou E; Kapsimalli V; Dagla K; Stamouli M; Gkirkas K; Konsta E; Karagiannidou A; Gkodopoulos K; Stavroulaki G; Pappa V; Angelopoulou M; Lowdell M; Tsirigotis P
Leuk Lymphoma; 2019 Oct; 60(10):2457-2463. PubMed ID: 30947589
[TBL] [Abstract][Full Text] [Related]
27. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the Groupe Francophone des Myelodysplasies.
Prebet T; Delaunay J; Wattel E; Braun T; Cony-Makhoul P; Dimicoli S; Wickenhauser S; Lejeune J; Chevret S; Chermat F; Fenaux P; Vey N;
Br J Haematol; 2018 Mar; 180(5):735-737. PubMed ID: 27977052
[No Abstract] [Full Text] [Related]
28. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Navada SC; Garcia-Manero G; OdchimarReissig R; Pemmaraju N; Alvarado Y; Ohanian MN; John RB; Demakos EP; Zbyszewski PS; Maniar M; Woodman RC; Fruchtman SM; Silverman LR
Leuk Res; 2020 Jul; 94():106369. PubMed ID: 32442785
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
30. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
31. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
Stevens B; Winters A; Gutman JA; Fullerton A; Hemenway G; Schatz D; Miltgen N; Wei Q; Abbasi T; Vali S; Singh NK; Drusbosky L; Cogle CR; Hammes A; Abbott D; Jordan CT; Smith C; Pollyea DA
Leuk Res; 2019 Jun; 81():43-49. PubMed ID: 31009835
[TBL] [Abstract][Full Text] [Related]
32. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
33. Infection Rate and Risk Factors in Patients Treated With Azacitidine.
Orero M; Villegas C; Ortiz S; Javier KP; Costa S; Pérez PL; Roig M; Linares M
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):e141-2. PubMed ID: 26257105
[No Abstract] [Full Text] [Related]
34. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
35. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
[TBL] [Abstract][Full Text] [Related]
36. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
Falantes J; Delgado RG; Calderón-Cabrera C; Márquez-Malaver FJ; Valcarcel D; de Miguel D; Bailén A; Bargay J; Bernal T; González-Porras JR; Tormo M; Ramos F; Andreu R; Xicoy B; Nomdedeu B; Brunet S; Sánchez J; Jurado AF; Bonanad S; Pérez-Simón JA; Sanz G;
Leuk Res; 2015 Jan; 39(1):52-7. PubMed ID: 25487012
[TBL] [Abstract][Full Text] [Related]
37. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
[TBL] [Abstract][Full Text] [Related]
38. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
Thepot S; Boehrer S; Seegers V; Prebet T; Beyne-Rauzy O; Wattel E; Delaunay J; Raffoux E; Hunault M; Jourdan E; Chermat F; Sebert M; Kroemer G; Fenaux P; Adès L;
Leuk Res; 2014 Dec; 38(12):1430-4. PubMed ID: 25449687
[TBL] [Abstract][Full Text] [Related]
39. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
[TBL] [Abstract][Full Text] [Related]
40. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Daver N; Kantarjian H; Garcia-Manero G; Jabbour E; Borthakur G; Brandt M; Pierce S; Vaughan K; Ning J; Nogueras González GM; Patel K; Jorgensen J; Pemmaraju N; Kadia T; Konopleva M; Andreeff M; DiNardo C; Cortes J; Ward R; Craig A; Ravandi F
Haematologica; 2017 Oct; 102(10):1709-1717. PubMed ID: 28729302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
